216 related articles for article (PubMed ID: 22234748)
1. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
Cohen M; Jeske WP; Nicolau JC; Montalescot G; Fareed J
J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
[TBL] [Abstract][Full Text] [Related]
2. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
3. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
Nicolau JC; Cohen M; Montalescot G
J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
[TBL] [Abstract][Full Text] [Related]
4. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
5. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
6. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
7. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
8. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
9. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
10. A consensus conference on complex biologics and low molecular weight heparins.
Kalodiki E; Fareed J; Tapson VF; Hoppensteadt DA; Sussman I; Carter CA; Parker S; Harenberg J; Hull R; Rao G; Lovinger DF; Ried LD; Kakkar A; Talarico L; Ofuso F; Bussey HI; Fanikos J; Groce JB; Skinner N; Ahluwalia M; Iqbal O; Jackson CM; Jeske WP; Georges M; Ramacciotti E; Tapson VF; Van Thiel D; Wahi R; Walenga J
Int Angiol; 2010 Apr; 29(2):193-6. PubMed ID: 20351676
[No Abstract] [Full Text] [Related]
11. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
12. Generic forms of low-molecular-weight heparins: some practical considerations.
Leong W; Hoppensteadt DA
Clin Appl Thromb Hemost; 2003 Oct; 9(4):293-7. PubMed ID: 14653438
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
14. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
15. Low molecular weight heparins copies: are they considered to be generics or biosimilars?
Minghetti P; Cilurzo F; Franzé S; Musazzi UM; Itri M
Drug Discov Today; 2013 Mar; 18(5-6):305-11. PubMed ID: 23153556
[TBL] [Abstract][Full Text] [Related]
16. Similar concerns. Safety, costs among the issues to be weighed as FDA grapples with crafting an approval process for generic versions of biological medicines.
Daly R
Mod Healthc; 2011 Jul; 41(28):38-40. PubMed ID: 21853593
[No Abstract] [Full Text] [Related]
17. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
Harenberg J; Kalodiki E; Walenga JM;
Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
[No Abstract] [Full Text] [Related]
18. Low molecular weight heparins: differences and similarities in approved preparations in the United States.
Bick RL; Fareed J
Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S63-6. PubMed ID: 10726038
[TBL] [Abstract][Full Text] [Related]
19. Generic and commercial low molecular weight heparins.
Messmore HL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):253. PubMed ID: 16959678
[No Abstract] [Full Text] [Related]
20. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
Fareed J; Haas S; Sasahar A
Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
